09-22-05

Express Mail No. EV475141657US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Acation of:

Santini, Jr. et al.

Confirmation No.:

6323

Serial No.:

10/768,315

Art Unit:

3738

Filed:

January 30, 2004

Examiner:

Phan, Hieu

For:

STENT FOR CONTROLLED

Attorney Docket No.:

10177-291-999

RELEASE OF DRUG

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure provisions of 37 C.F.R. §1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the application.

١.	Enclos	Enclosures accompanying this Information Disclosure Statement are:						
	la.	A list of all patents, publications, applications, or other information submitted for consideration by the office.						
	1 b.	A legible copy of:						
		☐ Each publication or that portion which caused it to be listed on the PTO-1449;						
		For each cited pending U.S. application filed before June 30, 2003, the application specification including the claims, and any drawing of the application, or portion of the application which caused it to be listed on the PTO-1449 including any claims directed to that portion;						
		all other information or portion which caused it to be listed on the PTO-1449.						
	1c.	An English language copy of search report(s) from a counterpart foreign application or PCT International Search Report.						
	ld.	Explanations of relevancy (ATTACHMENT 1(d), hereto) or English language abstracts of the non-English language publications.						
	le.	Pursuant to 37 C.F.R. § 1.98(a)(2)(ii), copies of the cited U.S. patents and U.S. patent application publications are not submitted herewith.						
2.		This Information Disclosure Statement is filed under 37 C.F.R. §1.97(b): Within three months of the filing date of a national application other than a continued prosecution application under §1.53(d);						
		Within three months of the date of entry of the national stage as set forth in						

		Before the mailing of the first Office action on the merits;			
		Before the mailing of a first Office action after the filing of a request for continued examination under §1.114.			
3.	This Information Disclosure Statement is filed under 37 C.F.R. §1.97(c) after the period specified in 37 C.F.R §1.97(b), but before the mailing date of any of a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311 or an action that otherwise closes prosecution in the application.				
		(Check either Item 3a or 3b)			
	3a.	The Certification Statement in Item 5 below is applicable. Accordingly, no fee is required.			
	3b.	The \$180.00 fee set forth in 37 C.F.R. §1.17(p) in accordance with 37 C.F.R. §1.97(c) is:			
		 ☐ enclosed ☒ to be charged to Jones Day Deposit Account No. 50-3013. 			
		(Item 3b to be checked if any reference known for more than 3 months)			
4.	 period	This Information Disclosure Statement is filed under 37 C.F.R. §1.97(d) after the specified in 37 C.F.R. §1.97(c), but on or before the date of payment of the issue fee.			
	The Ce	ertification Statement in Item 5 below is applicable.			
		The \$180.00 fee set forth in 37 C.F.R. §1.17(p) is: enclosed.			
		to be charged to Jones Day Deposit Account No. 50-3013			
5.		Certification Statement (applicable if Item 3a or Item 4 is checked)			
		(Check either Item 5a or 5b)			
	5a.	In accordance with 37 C.F.R. §1.97(e)(1), it is certified that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.			
	5b.	Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, and the communication was not received by any individual designated in 37 C.F.R. §1.56(c) more than thirty days prior to the filing of this information disclosure statement.			
	5c.	Pursuant to 37 C.F.R. §1.704(d), each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, and the communication was not received by any individual designated in 37 C.F.R. §1.56(c) more than thirty days prior to the filing of this information disclosure statement.			
6.	\boxtimes	This application is a continuation application under 37 C.F.R. §1.53(b) or (d).			
		(Check appropriate Items 6a, 6h and/or 6c)			

-2-

	6a. A Petition to Withdraw from issue under 37 C.F.R. §1.313(b)(5) is concur filed herewith.							
	6b.	No. 10/637,319, fi	tions listed on Form PTO-1449 from prior apiled on 8/3/03, of which this application clair re not being submitted pursuant to 37 C.F.R.	ns priority under				
	6c.	Copies of the publication S	lications listed on Form PTO-1449 were not Serial No. , filed on , and are pro	previously cited in vided herewith.				
7.	\boxtimes	This is a Supplementa	l Information Disclosure Statement. (Check	Item 7a)				
	7a.	supplements the In attempt was made were made. These additional time is	Il Information Disclosure Statement under 37 information Disclosure Statement filed on 1/10 to comply with 37 C.F.R. §1.98, but inadve e omissions have been corrected herein. Accordance of the considered as if properly filed on 1/19/05.	9/05. A bona fide rtent omissions cordingly,				
8.	In accordance with 37 C.F.R. §1.98, a concise explanation of what is presently understood to be the relevance of each non-English language publication is:							
	(Check Item 8a, 8b, or 8c)							
	8a. satisfied because all non-English language publications were cited on the enclosed English language copy of the PCT International Search Report or the search report from a counterpart foreign application indicating the degree of relevance found by the foreign office.							
8b. set forth in the application.								
	8c. enclosed as an attachment hereto.							
9.	The Commissioner is authorized to charge any additional fee required or credit any overpayment for this Information Disclosure Statement and/or Petition to Jones Day Deposit Account No. 50-3013.							
10.	No admission is made that the information cited in this Statement is, or is considered to be, material to patentability and no representation is made that a search has been made (other than a search report of a foreign counterpart application or PCT International Search Report if submitted herewith). 37 C.F.R. §§1.97(g) and (h).							
			Respectfully submitted,					
Date:	Sente	mber 20, 2005	10	54,390				
Suic.	Sepie		Breyt P. Ray JONES DAY 222 East 41st Street New York, New York 10017 (212) 326-3939	(Reg. No.)				

1 4		<u>a</u>									
AU5 Z	2005	E E				ATTY. DOCKET NO.		APPLICATIO			
E.	ALC:	y		PE 402		10177-294-999		10/637,3			
		(Use several sheets if n	ecessary	0 5000,	읽	Santini, Jr. et al.					
			(,	5EP 11	MAKOFFICE	FILING DATE		GROUP			
	\ a								3744		
U.S. PATENT DOCUMENTS											
*EXAMINER		DOCUMENT MUMBER	DATE		AME	CLASS	SUBCLASS	FILING D			
INITIAL	A01	2002/0038146	03/28/2002	Наггу		AME .	CLASS	SUBCLASS	IF AFFROR	MATE	
	A02	6,783,543 B2	08/31/2004	Jang							
	A03	6,709,379 B1	03/23/2004	Brandau et a	1.						
	A04	6,638,302 B1	10/28/2003	Curcio et al.	_						
	A05	6,558,422 B1	05/062003	Baker et al.							
	A06	6,491,666 B1	12/10/2002	Santini et al.							
	A07	6,395,326 B1	05/28/2002	Castro et al.							
				Hossainy et al.							
<u></u>	A09	6,273,913 B1	08/14/2001	Wright et al.							
	AIO	6,273,908 B1	08/14/2001	Ndondo-Lay							
	All	6,096,070	08/01/2000	Ragheb et al.							
•	A12	6,071,305	06/06/2000	Brown et al.							
	A13	5,891,108	04/06/1999	Leone et al.							
			<u></u>	L			-	L			
•			FOREIGN	PATENT I	DOC	UMENTS					
		DOCUMENT NUMBER	DATE		cou	INTRY	CLASS	SUBCLASS	TRANSLA	ATION	
•	B01	1	1	1				1	YES	NO	
	B02										
	B03			1							
	B03	<u> </u>	Í	<u></u>				<u> </u>	<u> </u>		
		OTHER REFERE	NCES (Incl	uding Author	r, Titl	le, Date, Pertinent	Pages, I	Etc.)			
	C01						• • • •				
	C02										
	C03				_						
EXAMINER		,			ATE (CONSIDERED					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.											
								-			